deltatrials
Completed PHASE2 NCT00049725

Daclizumab to Treat Chronic Immune Thrombocytopenia

A Study of Daclizumab in Chronic Immune Thrombocytopenia (ITP)

Sponsor: National Institutes of Health Clinical Center (CC)

Conditions Thrombocytopenia
Interventions Daclizumab
Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Nov 30, 2002 Completion: Dec 31, 2004

This PHASE2 trial investigates Thrombocytopenia and is currently completed. National Institutes of Health Clinical Center (CC) leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Nov 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institutes of Health Clinical Center (CC)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States